The value of octreotide scintigraphy in patients with lung cancer
- 1 October 1994
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 21 (10) , 1106-1113
- https://doi.org/10.1007/bf00181066
Abstract
We evaluated octreotide scintigraphy in 81 untreated patients who were suspected of having bronchial carcinoma. Octreotide scintigraphy visualized the primary tumour in all of 40 patients with non-smallcell lung carcinoma (non-SCLC), and all of 26 patients with SCLC. In the remaining patients, other bronchial disease and metastases from extrapulmonary carcinomas were also visualized. Mediastinal lymph node involvement and distant metastases were recognized in 5 of 15 and 1 of 7 patients with non-SCLC, respectively. In vitro, none of the non-SCLCs were shown to bear somatostatin receptors. We postulate that the visualization of non-SCLC during octreotide scintigraphy is caused by binding of labelled octreotide to activated leucocytes or to proliferating neuroendocrine cells around the tumours. In patients with SCLC, radiologically suspected lymph node involvement was visualized for 21 of 25 sites. Distant metastases, especially to the liver and abdomen, were missed for 14 of 20 sites, most probably because no laxatives were administered and single photon emission tomography of the abdomen was not performed. The failure to recognize liver metastases is most probably due to a comparable uptake of radioactivity by the surrounding normal liver tissue. In 15 of 26 patients, previously unrecognized tumour sites were suggested during octreotide scintigraphy, leading to a downstaging of 5 of 14 patients with limited disease. Unexpected cerebral metastases were suggested in five patients with either limited or extensive disease. In all four of these for whom follow-up was available, cerebral metastases became manifest 5–8 months after octreotide scintigraphy. We conclude (1) that octreotide scintigraphy is of no use to differentiate SCLC from other lung disease, and (2) that octreotide scintigraphy should be included in the staging procedure of SCLC because it may allow early detection of metastases, especially to the brain.Keywords
This publication has 25 references indexed in Scilit:
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993
- Somatostatin analogue scintigraphy in carcinoid tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993
- In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in ratsLife Sciences, 1991
- [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validationLife Sciences, 1991
- The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of TumorsEndocrine Reviews, 1991
- Transferrin Receptor Expression in Adenocarcinoma of the Lung as a Histopathologic Indicator of PrognosisChest, 1990
- Somatostatin receptors are present in small‐cell but not in non‐small‐cell primary lung carcinomas: Relationship to EGF‐receptorsInternational Journal of Cancer, 1990
- In vitro and in vivo inhibition of human small cell lung carcinoma (NCl-H69) growth by a somatostatin analogueBiochemical and Biophysical Research Communications, 1988
- Distribution of somatostatin receptors on murine spleen and Peyer's patch T and B lymphocytesBrain, Behavior, and Immunity, 1987
- Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancerNature, 1985